Cellectis (CLLS) a clinical-stage biopharmaceutical company whose mission reads that it's "dedicated to providing life-saving UCART product candidates to address unmet needs for multiple cancers." With over 20 years of expertise in gene editing, the company has been in deep research to harness the power of the immune system in order to target and eradicate cancer cells utilizing its gene-editing technology TALEN and pioneering electroporation system PulseAgile.
As gene editing becomes a more pronounced medical practice, the future for companies like Cellectis, as well as some peers in the practice like Crispr